Parr Mcknight Wealth Management Group LLC Has $909,000 Stock Position in Eli Lilly and Company $LLY

Parr Mcknight Wealth Management Group LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 74.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,192 shares of the company’s stock after selling 3,490 shares during the quarter. Parr Mcknight Wealth Management Group LLC’s holdings in Eli Lilly and Company were worth $909,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Palumbo Wealth Management LLC increased its holdings in shares of Eli Lilly and Company by 4.2% during the 3rd quarter. Palumbo Wealth Management LLC now owns 1,035 shares of the company’s stock worth $790,000 after purchasing an additional 42 shares during the period. Apriem Advisors lifted its stake in shares of Eli Lilly and Company by 12.9% in the third quarter. Apriem Advisors now owns 1,940 shares of the company’s stock valued at $1,480,000 after buying an additional 221 shares during the period. Mufg Securities Americas Inc. lifted its stake in shares of Eli Lilly and Company by 23.0% in the third quarter. Mufg Securities Americas Inc. now owns 21,439 shares of the company’s stock valued at $16,358,000 after buying an additional 4,005 shares during the period. Lake Street Private Wealth LLC grew its position in Eli Lilly and Company by 4.0% during the third quarter. Lake Street Private Wealth LLC now owns 6,559 shares of the company’s stock worth $5,004,000 after buying an additional 250 shares in the last quarter. Finally, Baldwin Investment Management LLC increased its stake in Eli Lilly and Company by 15.7% during the third quarter. Baldwin Investment Management LLC now owns 11,079 shares of the company’s stock valued at $8,453,000 after acquiring an additional 1,505 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have commented on LLY shares. Bank of America reduced their price objective on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research report on Monday, December 15th. Rothschild & Co Redburn boosted their price objective on Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a research report on Monday, January 26th. HSBC reaffirmed a “hold” rating and issued a $1,070.00 target price on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Wolfe Research lifted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Finally, The Goldman Sachs Group set a $1,260.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,229.33.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,042.68 on Wednesday. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The company has a market capitalization of $983.62 billion, a PE ratio of 45.43, a price-to-earnings-growth ratio of 1.23 and a beta of 0.39. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The business has a 50 day simple moving average of $1,054.49 and a 200 day simple moving average of $923.72.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same period in the prior year, the business posted $5.32 earnings per share. The business’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is currently 30.15%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Head‑to‑head trial news showing Novo’s next‑gen obesity candidate underperformed Lilly’s tirzepatide has strengthened expectations that Lilly will retain market share in the high-growth weight‑loss category; that data triggered earlier upside in LLY. Trial Readout Lifts Lilly
• Positive Sentiment: Lilly launched an FDA‑cleared multi‑dose KwikPen for Zepbound (tirzepatide), giving patients a more convenient monthly device at the same self‑pay price — a commercial move intended to improve adherence and retention. Zepbound KwikPen Launch
• Positive Sentiment: Wall Street remains constructive on LLY’s longer‑term outlook (Goldman and other analysts keep Buy/Outperform calls and elevated price targets), supporting the stock’s valuation against the sector noise. Analyst Support
• Neutral Sentiment: Early clinical work showing benefit of combining Zepbound with other therapies (e.g., Taltz) and investor commentary on retention strategies (multi‑dose pen) add incremental optionality but are not immediate revenue drivers. Pipeline/Combo Data
• Negative Sentiment: Nuevo pricing shock — Novo Nordisk announced U.S. list price cuts of up to ~50% for Ozempic/Wegovy (to ~$675/month starting 2027). That move has rattled the sector, and LLY shares have slipped as investors reassess pricing dynamics and potential margin/market‑share impacts across GLP‑1s. Novo Price Cut Hits Stocks
• Negative Sentiment: Broader competition and pricing pressure could compress realized prices or accelerate payer negotiations over time, a structural risk to growth if competitors follow price cuts or insurers demand steeper discounts. Price Competition Risk

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.